Asklepios Fachkliniken München-Gauting
In research, Asklepios Fachkliniken München-Gauting stands highest in Medicine (#6,613 of 17,978 worldwide), Health Sciences (#8,797 of 20,462 worldwide) and Pulmonary and Respiratory Medicine (#1,279 of 2,717 worldwide), over all time. Relative to its size it is most specialised in Pulmonary and Respiratory Medicine — Pulmonary and Respiratory Medicine is 16.9× its share of world research.
- World rank, 2022–2025
- #19,133 of 28,054 · #17,739 all time
- Rank in Germany
- #751 of 1,178
- Research works
- 757 ▲ 44% vs 2013–17
- Citations
- 12k 16.5 per fractional work
- Top-10% rate
- 8.8% record average 16.5%
- Open access
- 19% world 28%
What is Asklepios Fachkliniken München-Gauting known for in research?
The fields where it stands highest, over all time, ranked among every institution above the floor in each field.
| Field | World rank | Where that sits | Top-10% rate | Works |
|---|---|---|---|---|
| MedicineField | #6,613 of 17,978 | 10.0% | 509 | |
| Health SciencesDomain | #8,797 of 20,462 | 9.6% | 534 | |
| Pulmonary and Respiratory MedicineSubfield | #1,279 of 2,717 | 10.3% | 249 |
Each strip is that field’s whole ranked pool, with the notch where Asklepios Fachkliniken München-Gauting sits in it, in the colour of the band that rank falls in. The track under the rate is the rate itself: it carries no world mark, because the world rate differs by field (from about 6% to 21% in this record).
What does Asklepios Fachkliniken München-Gauting specialise in?
Where its research is concentrated relative to its size: Pulmonary and Respiratory Medicine takes 16.9× the share of its output that it takes of world research.
- Pulmonary and Respiratory MedicineSubfield · 20.5 works17×
Location quotient, a volume reading rather than an impact one. It surfaces small, lopsided specialities.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 3.8×. Every wedge is a field page.
- Immunology and Microbiology 3.8×
- Business, Management and Accounting 3.2×
- Medicine 3.0×
- Health Professions 1.2×
- Psychology 1.1×
- Biochemistry, Genetics and Molecular Biology 0.9×
- Arts and Humanities 0.9×
- Social Sciences 0.7×
- Veterinary 0.5×
- Economics, Econometrics and Finance 0.5×
- Neuroscience 0.5×
- Physics and Astronomy 0.4×
- Dentistry 0.2×
- Agricultural and Biological Sciences 0.1×
- Chemistry 0.1×
- Environmental Science 0.1×
- Engineering 0.0×
- Mathematics 0.0×
- Computer Science 0.0×
- Materials Science 0.0×
Who are the top researchers at Asklepios Fachkliniken München-Gauting?
Ranked on the composite score, Joachim von Pawel, Niels Reinmuth and O Karg lead among researchers whose main affiliation is Asklepios Fachkliniken München-Gauting.
- 1 Joachim von Pawel Germany · #41,001 worldwide 370 citations · 60 works
- 2 Niels Reinmuth Germany · #42,420 worldwide 361 citations · 66 works
- 3 O Karg Germany · #455,123 worldwide 37 citations · 20 works
- 4 Michael Lindner Germany · #465,827 worldwide 79 citations · 43 works
- 5 Horst Avenarius Germany · #594,537 worldwide 3 citations · 22 works
- 6 Thomas Duell Germany · #635,379 worldwide 64 citations · 16 works
- 7 Jens Geiseler Germany · #817,398 worldwide 27 citations · 19 works
- 8 W Wöckel Germany · #822,221 worldwide 18 citations · 25 works
- 9 Wolfgang Gesierich Germany · #1,195,200 worldwide 14 citations · 40 works
- 10 Harald Hoffmann Germany · #1,247,467 worldwide 13 citations · 20 works
Which keywords describe research at Asklepios Fachkliniken München-Gauting?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Chemotherapy, Targeted Therapy, Clinical Trials, Digital Transformation, Sustainable Development, Diagnosis, Management and Immunotherapy.
- Socio-Technical Systems
- Agility
- Small-Cell Lung Cancer
- Genomic Profiles
- Business Models
- Metastasis
- PD-1 and PD-L1
- Immune Checkpoint Blockade
- Organizational Change
- Epithelial-Mesenchymal Transition
- Big Data
- EGFR Mutations
- ALK Inhibitors
- Social Innovation
- Treatment Guidelines
- Adjuvant Therapy
- Immunotherapy
- Diagnosis
- Clinical Trials
- Sustainable Development
- Chemotherapy
- Targeted Therapy
- Digital Transformation
- Management
- Leadership
- Radiotherapy
- Interdisciplinary Research
- Tumor Microenvironment
- CT Screening
- Lung Cancer
- Biomarkers
- Fibrosis
- Prognostic Factors
- Interstitial Lung Disease
- Idiopathic Pulmonary Fibrosis
- TGF-ß
- Customer Experience
- Pulmonary Hypertension
- Tumor Markers
- Mechanical Ventilation
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Chemotherapy7▲ 13×15 topics
- Sustainable Development6▲ 4.7×4 topics
- Targeted Therapy6▲ 33×5 topics
- Clinical Trials6▲ 10×3 topics
- Digital Transformation5▲ 13×5 topics
- Diagnosis5▲ 6.8×15 topics
- Management4▲ 7.2×12 topics
- Immunotherapy4▲ 7.5×10 topics
- Leadership4▲ 10×4 topics
- Adjuvant Therapy4▲ 36×2 topics
- Radiotherapy4▲ 12×5 topics
- Treatment Guidelines4▲ 20×2 topics
- Interdisciplinary Research3▲ 48×1 topic
- Social Innovation3▲ 27×1 topic
- Tumor Microenvironment3▲ 9.3×5 topics
- ALK Inhibitors3▲ 64×1 topic
- CT Screening3▲ 59×1 topic
- EGFR Mutations3▲ 64×1 topic
- Lung Cancer3▲ 23×1 topic
- Big Data3▲ 4.1×4 topics
- Biomarkers3▲ 5.1×7 topics
- Epithelial-Mesenchymal Transition3▲ 37×3 topics
- Fibrosis3▲ 18×3 topics
- Organizational Change3▲ 46×2 topics
- Prognostic Factors3▲ 7.9×5 topics
- Immune Checkpoint Blockade2▲ 29×1 topic
- Interstitial Lung Disease2▲ 51×2 topics
- PD-1 and PD-L12▲ 29×1 topic
- Idiopathic Pulmonary Fibrosis2▲ 66×1 topic
- Metastasis2▲ 8.8×4 topics
- TGF-ß2▲ 20×1 topic
- Business Models2▲ 42×1 topic
- Customer Experience2▲ 20×1 topic
- Genomic Profiles2▲ 68×1 topic
- Pulmonary Hypertension2▲ 21×2 topics
- Small-Cell Lung Cancer2▲ 68×1 topic
- Tumor Markers2▲ 36×2 topics
- Agility2▲ 200×1 topic
- Mechanical Ventilation2▲ 25×2 topics
- Socio-Technical Systems2▲ 117×1 topic
Which research topics does Asklepios Fachkliniken München-Gauting publish most on?
By volume in 2022–2025: Innovation, Technology, and Society, Lung Cancer Diagnosis and Treatment, Lung Cancer Treatments and Mutations and Cancer Immunotherapy and Biomarkers.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Innovation, Technology, and Society Sociology and Political Science 3 works
- 2 Lung Cancer Diagnosis and Treatment Pulmonary and Respiratory Medicine 3 works
- 3 Lung Cancer Treatments and Mutations Pulmonary and Respiratory Medicine 3 works
- 4 Cancer Immunotherapy and Biomarkers Oncology 2 works
- 5 Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis Pulmonary and Respiratory Medicine 2 works
- 6 Digital Innovation in Industries Management of Technology and Innovation 2 works
- 7 Lung Cancer Research Studies Oncology 2 works
- 8 Corporate Management and Leadership Organizational Behavior and Human Resource Management 2 works
- 9 Neonatal Respiratory Health Research Pulmonary and Respiratory Medicine 2 works
- 10 Chronic Obstructive Pulmonary Disease (COPD) Research Pulmonary and Respiratory Medicine 2 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Asklepios Fachkliniken München-Gauting's research output changed?
Output in 2018–2022 was 44% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Gauting
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.